Chenkai Jiang
ABSTRACT
This article reviews the research progress of the spike protein of the virus SARS-CoV-2 that causes COVID-19, including the gene sequence and protein sequence encoding the spike protein, as well as its secondary and tertiary structure through bioinformatics tools. The sequence similarlity comparsion results show that the spike protein has many homologous proteins and the highest similarity is SPIKE_Bat SARS-like CoV, which was also a spike glycoprotein from Bats.Secondary structure prediction shows that the sequence from position 1196 to 1218 occurs across the membrane and the protein has a several secondary domains which are potentially helpful for the virus to infect host cells ; Next, we found that the spike glycoprotein is predicted as a trimer which is extremely useful to bind the ACE2. In addition, this review also summarized the monoclonal antibody drugs targeting the spike protein, as well as several small molecule drugs, and made a comprehensive view for the treatment of COVID-19.
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020). 10.1016/S0140-6736(20)30183-5Google Scholar
Cross Ref
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses , The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020). 10.1038/s41564-020-0695-zGoogle Scholar
- Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., Chen H.-D., Chen J., Luo Y., Guo H., Jiang R.-D., Liu M.-Q., Chen Y., Shen X.-R., Wang X., Zheng X.-S., Zhao K., Chen Q.-J., Deng F., Liu L.-L., Yan B., Zhan F.-X., Wang Y.-Y., Xiao G.-F., Shi Z.-L., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). 10.1038/s41586-020-2012-7Google ScholarCross Ref
- Tian X, Li C, Huang A, Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382-385. Published 2020 Feb 17. doi:10.1080/22221751.2020.1729069Google Scholar
- Joyce MG, Sankhala RS, Chen WH, A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein. Preprint. bioRxiv. 2020;2020.03.15.992883. Published 2020 Mar 17. doi:10.1101/2020.03.15.992883Google Scholar
- Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi:10.1016/j.ijantimicag.2020.105954Google Scholar
- Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-818. doi:10.1002/jmv.25801Google Scholar
- Wang C, Li W, Drabek D, A human monoclonal antibody blocking SARS-CoV-2 infection [published correction appears in Nat Commun. 2020 May 14;11(1):2511]. Nat Commun. 2020;11(1):2251. Published 2020 May 4. doi:10.1038/s41467-020-16256-yGoogle Scholar
- Edward N. van den Brink, Jan ter Meulen, Freek Cox, Mandy A. C. Jongeneelen. Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology Jan 2005, 79 (3) 1635-1644; DOI: 10.1128/JVI.79.3.1635-1644.2005Google Scholar
- Bhagavathula AS, Aldhaleei WA, Rovetta A, Rahmani J. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. Cureus. 2020;12(5):e8342. Published 2020 May 28. doi:10.7759/cureus.8342Google Scholar
- Wu Y, Wang F, Shen C, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274-1278. doi:10.1126/science.abc2241Google Scholar
- Pinto D, Park YJ, Beltramello M, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290-295. doi:10.1038/s41586-020-2349-yGoogle Scholar
- Wrapp D, De Vlieger D, Corbett KS, Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 2020;181(6):1436-1441. doi:10.1016/j.cell.2020.05.047Google Scholar
- Ju, B., Zhang, Q., Ge, J. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature (2020). https://doi.org/10.1038/s41586-020-2380-zGoogle Scholar
- Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92(5):479-490. doi:10.1002/jmv.25707Google Scholar
- Wang M, Cao R, Zhang L, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Feb 4. doi: 10.1038/s41422-020-0282-0.Google Scholar
- Savarino A, Di Trani L, Donatelli I, New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6:67-9Google Scholar
- Keyaerts E, Vijgen L, Maes P, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323:264-8.Google Scholar
- Vincent MJ, Bergeron E, Benjannet S, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.Google Scholar
- Sperber K, Quraishi H, Kalb TH, Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol. 1993;20:803-8.Google Scholar
- Quan Wang, Jiqin Wu, Haofeng Wang. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase. Cell, 2020 May 22. DOI:https://doi.org/10.1016/j.cell.2020.05.034Google Scholar
Recommendations
Targeting COVID-19 (SARS-CoV-2) main protease through active phytocompounds of ayurvedic medicinal plants – Emblica officinalis (Amla), Phyllanthus niruri Linn. (Bhumi Amla) and Tinospora cordifolia (Giloy) – A molecular docking and simulation study
AbstractCoronavirus Disease-2019 (COVID-19), a viral disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was declared a global pandemic by WHO in 2020. In this scenario, SARS-CoV-2 main protease (COVID-19 Mpro), an ...
Highlights- 96 bioactive compounds were screened computationally to search potential inhibitors for COVID-19 Main protease.
Camphor, Artemisinin and Sumac Phytochemicals as inhibitors against COVID-19: Computational approach
AbstractCovid-19 is an emerging infectious disease caused by coronavirus SARS-CoV-2. Due to the rapid rise in deaths resulted from this infection all around the world, the identification of drugs against this new coronavirus is an important ...
Highlights- Hinokiflavone and Myricetin are the structures with best affinity and stability in the binding site of the studied enzyme.
A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment
AbstractThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 1.4 million deaths worldwide. Repurposing existing drugs offers the fastest opportunity to identify new indications for existing drugs as a stable solution against ...
Graphical abstractDisplay Omitted
Highlights- 1865 drugs from KCB-DR database were screened to search potential inhibitors for COVID-19.
- Drugs were screened by molecular docking, MD simulations, and binding free energy calculations.
- Telaprevir and ceftaroline fosamil were ...
Comments